ADGERO BIOPHARMACEUTICALS HOLDINGS INC
Photodynamic therapy treatment to prevent arteriovenous fistula maturation failure in hemodialysis patients
- Sector
- Medtech
- Headquarters
- Princeton, NJ
- Founded
- 2015
- Latest Form D
- $459K, Sep 2016
- Total capital
- $4M
- Federal grants
- $450K
- 2 awards · 2020
- Rank in peer group#287 of 542
- Private capital raised
- $3.5M
- 3 Form D · last Sep 2016
- 122 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 4 pending
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · Photodynamic Therapy to Prevent Arteriovenous Fistula Maturation Failure$225K
- Federal grantHealth and Human S · Phase I · Photodynamic Therapy to Prevent Arteriovenous Fistula Maturation Failure$225K
- Private capital raisedForm D · SEC · 3rd filing$459K
- Private capital raisedForm D · SEC · 2nd filing$3M
- Private capital raisedForm D · SEC · 1st filing$40K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 542 peers
Line = medianMedtech · Device
- Federal grantsBelow median
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Allen P. BloomDirectorNamed in SEC Form D filings
- David P. HochmanDirectorNamed in SEC Form D filings
- Frank P. PilkiewiczExecutive Officer, DirectorNamed in SEC Form D filings
- John BrancaccioExecutive OfficerNamed in SEC Form D filings
- Roman P. Perez-SolerDirectorNamed in SEC Form D filings
- Steve P. RychnovskyExecutive OfficerNamed in SEC Form D filings
Show all 7 people
- Tim P. McInerneyDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 4- PendingMethods for the Production of Nickel (II) Etioporphyrin-IUSPTOApplication 17614132
- PendingMethods For Treating Cutaneous Metastatic CancersUSPTOApplication 17546715
- PendingMethods For Treating Cutaneous Metastatic CancersUSPTOApplication PCTUS2021062603
Show all 4 patent records
- Methods for the Production of Nickel (II) Etioporphyrin-IJun 1, 2023 · Application 17614132Pending
- Methods For Treating Cutaneous Metastatic CancersJun 16, 2022 · Application 17546715Pending
- Methods For Treating Cutaneous Metastatic CancersApplication PCTUS2021062603Pending
- Methods For The Production Of Nickel (II) Etioporphyrin-iApplication PCTUS2021053362Pending
Related companies, and why
- DPX Technologies, LLCSimilar federal contract value in Medtech · null in contracts
- SAUREUS, INC.Similar federal contract value in Medtech · null in contracts
- SPROUTEL, INC.Similar federal contract value in Medtech · null in contracts
- RIGHTAIR, LLCSimilar federal contract value in Medtech · null in contracts
- eSens LLCSimilar federal contract value in Medtech · null in contracts
- LIFESPAN TECHNOLOGIES LLCSimilar federal contract value in Medtech · null in contracts
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .